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Summary 
Cyclic-AMP is known to be released from cells and tissues and the 
amounts released have been reported to reflect intracellular CAMP levels. 
To measure CAMP release the phosphodiesterase inhibitor IBMX is often 
used to increase the amount of CAMP to a detectable l vel. Using this 
method to follow CAMP dynamics of melanotrope cells in the 
neurointermediate pituitary lobe of the amphibian Xenopus luevis we show 
that the a-MSH secrete-inhibitors baclofen (GABA, receptor agonist) and 
dopamine inhibit CAMP release, confirming the idea that these factors 
inhibit a-MSH secretion by reducing adenylyl cyclase activity. Using a 
sensitive CAMP radioimmunoassay wewere able to measure CAMP release 
from Xenopus neurointermediate lobes in the absence of IBMX. Both 
baclofen and dopamine appeared to inhibit a-MSH secretion but strongly 
stimulated the release of CAMP. This indicates that the extracellular CAMP 
level is not a reliable parameter tomeasure the intracellular CAMP level in 
the absence of IBMX. The data furthermore suggest that CAMP release is 
a physiologically regulated process, which might be involved in lowering 
intracellular CAMP levels associated with a cellular secretory compartment. 
No apparent differences could be found in the lobe content of CAMP at the 
termination of secrete-inhibitor t eatment, leading to the idea that the 
CAMP compartment associated with secretion is small relative to the total 
amount of CAMP present in the lobe. 
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The melanotrope cells in the neurointermediate lobe of the amphibian Xenopus laevis 
produce and secrete various proopiomelanocortin-derived bioactive peptides, including 
melanophore-stimulating hormone (c+MSH) (I). This peptide, which is released in animals that are 
kept on a black background, stimulates the dispersion of pigment in the dermal melanophores thus 
causing darkening of the skin (2). The secretion of a-MSH from the melanotropes i under 
complex stimulatory and inhibitory control: thyrotropin-releasing hormone (TRH) and corticotropin- 
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releasing hormone (CRH) stimulate secretion while y-aminobutyric acid (GABA), dopamine and 
neuropeptide Y are known inhibitors of a-MSH release. 
Various studies have indicated that regulation of cyclic adenosine-3’,5’-monophosphate 
(CAMP) production plays an important role in mediating signal transduction i  the Xenopus 
melanotropes and is especially involved in the inhibition of a-MSH secretion by GABA via a 
GABA, receptor and by dopamine via a dopamine D, receptor (3,4). It has also been shown that 
these cells, like many other cell types, release CAMP into the extracellular space ($6). The amount 
of CAMP released from Xenopus melanotrope cells is suggested to be proportional to the 
intracellular CAMP concentration (5). Such a relationship between extracellular and intracellular 
CAMP levels is assumed to be a general phenomenon (7). 
In many studies on the intracellular CAMP concentration isobutyl methylxanthine (IBMX) 
is applied because this inhibitor of phosphodiesterase enhances extracellular CAMP concentrations 
to such a degree that they can be readily determined. To get a better insight into the relationship 
between intracellular CAMP concentration and CAMP release from the Xenopus neurointermediate 
lobe we have examined intracellular and extracellular CAMP levels in the presence and absence 
of IBMX using a sensitive radioimmunoassay. The results indicate that inhibition of a-MSH by 
baclofen and dopamine is concomitant with a strong stimulation of CAMP release from the 
neurointermediate lobe, questioning the concept of proportionality between intracellular and 
extracellular CAMP levels. 
Methods 
Animals 
Adult Xenopus laevis were bred in our aquatic laboratory facility and adapted to a black 
background for four weeks prior to the experiments, under continuous illumination, at 22 “C. 
Superfusion 
Neurointermediate lobes were dissected and transferred to a superfusion system with four 
chambers, each chamber holding one lobe on a filter. The superfusion medium contained 112 mM 
NaCl, 2 mM KCl, 1.5 mM HEPES (pH 7.4, carbogen-aerated), 0.03% bovine serum albumin 
(fraction V, Sigma, St. Louis, MO, U.S.A.), 0.2% glucose and 1 mg/l ascorbic acid. Flow rate was 
1.6 ml/h and fractions were collected at 15 min intervals for radioimmunoassays of CAMP and a- 
MSH. The receptor agonists baclofen (Ciba-Geigy, Basel, Switzerland) and dopamine (Sigma) were 
added in various concentrations tothe superfusion medium. In some experiments 0.5 mM isobutyl 
methylxanthine (IBMX; Sigma) was present in the medium. After superfusion each lobe was 
homogenized in 0.1 N HCl and freeze-dried. Subsequently, the residue was supplied with 200 pl 
superfusion medium and CAMP was determined in aliquots of 10, 20 and 40 pl, made up to 100 
ul with superfusion medium, with the radioimmunoassay for CAMP. 
Radioimmunoassays 
The radioimmunoassay for a-MSH was applied as described previously (8). The CAMP contents 
of duplicate 100 ul aliquots of each fraction were estimated by radioimmunoassay in glass tubes, 
essentially according to 9,lO. Acetylation was performed by adding 5 pl of acetic anhydride and 
triethanolamine (v/v 1:2). Then 100 ul anti-CAMP serum, purchased from Dr J.C. Stoof (Dept. of 
Neurology, Medical Faculty, Free University, Amsterdam, The Netherlands) and 100 pl sodium 
acetate buffer (pH 6.3) containing 0.5% bovine serum albumin and 0.2% sodium azide were added. 
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~-CAMP was produced by the chloramine-T method (11) and purified according to our standard 
procedure for labeling of cr-MSH (12). As a standard, non-acetylated CAMP of Amersham (Little 
Chalfont, U.K.) was used. Bound and free ?-CAMP were separated by polyethylene glycol/henn 
egg albumin precipitation. Sensitivity of the assay was 2 fmol CAMP per sample. 
Calculations and statistics 
In the figures cc-MSH secretory data are shown as mean (n=4) with standard error of the mean 
(SEM; vertical bars) of percent basal release. The 100% basal release was defined as the mean 
amount of a-MSH measured in the three superfusion fractions immediately preceding the first 
treatment with a receptor agonist. Cyclic AMP levels are means of 4 samples per time point. Lobe 
contents were statistically analyzed with one-way analysis of variance (a = 5%)(13) followed by 
Duncan’s multiple range test (see 14). The analysis was preceded by tests for the joint assessment 
of normality (15) and the homogeneity of variance (Bartlett’s test, see 13). 
Results and Discussion 
First we established the effects of the inhibitory neural factors on a-MSH release and on the 
intracellular and extracellular concentrations of CAMP, in the presence of IBMX. Baclofen induced 
a decrease in CAMP contents of the neurointermediate lobe by about 30% (Fig. la) and a decrease 
in a-MSH release by 20% (Fig. 2a). Similarly, dopamine reduced both intracellular CAMP and a- 
MSH release, by 50 % and 70 %, respectively (Figs. la, 2b). These data confirm the idea that 
GABA and dopamine reduce a-MSH release by lowering the intracellular CAMP level in the 
melanotrope cells (6). As to the release of CAMP, both baclofen and dopamine inhibited this 
process, namely by about 40% and 50%, respectively (Figs 2c, 2d). This observation tits in with 
the common assumption that there is a fixed proportional relationship between intracellular and 
extracellular CAMP concentrations (7). 
FIG. 1 
Lobe contents of CAMP in the presence of IBMX (a) and without the 
phosphodiesterase inhibitor (b). The contents were at termination of the 
superfusion determined in the same lobes as used in the Figs. 2 and 3a-d. 
Error bars indicate +SEM (n=4). In (c) medium contents of CAMP are 
represented with and without IBMX (n=8). 
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Omitting IBMX from control media resulted into a decrease of about 2.5 times in the 
intracellular (Fig. lb) and extracellular levels of CAMP (Fig. lc). When lobes were treated with 
baclofen or dopamine in the absence of IBMX, a-MSH release was still clearly reduced compared 
to control obes (60% and 50%, respectively; Fig. 3a,b), but no significant change was noted with 
respect o the intracellular CAMP concentration (Fig. lb). Even more striking was that under these 
conditions the extracellular CAMP concentration was strongly elevated, with maximum increases 
from 2 up to 7 times (Fig. 3c,d, 4). Full stimulation was reached within 15-30 min and appeared 
to be completely reversed after removal of the inhibitor (Fig. 4). These increases in extracellular 
CAMP proved to be significant (P<=O.O5) and reproducible (4 independent experiments) and we 
therefore conclude that in the absence of IBMX, the degree of CAMP release is not proportional 
-Percent Bosoi Releose _____ ___.___ -.--.. -. .---- 
a--M% + 5*10-‘M IBMX 
120 . 
5 10 5 
Superfusion Froction Number 
10 
FIG. 2 
Release of immunoreactive or-MSH and CAMP egress from superfused 
neurointermediate lobes of Xenopus laevis in the presence of IBMX. 
Arrows represent the periods during which baclofen (BAC) or dopamine 
(DA) were present. In (c) and (d) egress of CAMP from the same lobes as 
in (a) and (b) is represented. Error bars indicate -SEM. 
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FIG. 3 
Release of immunoreactive a-MSH and CAMP egress from superfused 
neurointermediate lobes of Xenopus luevis without IBMX. Arrows represent 
the periods during which baclofen (BAC) or dopamine (DA) were present. 
In (c) and (d) egress of CAMP from the same lobes as in (a) and (b) is 
represented. 
to the CAMP level within the neurointermediate lobe. We assume that the common observation ot 
proportionality between intracellular and extracellular CAMP levels may be due in at least a 
number of cases to the use of IBMX that inhibits intracellular breakdown of CAMP. Consequently, 
it should be strongly questioned whether under physiological conditions (i.e., in the absence of 
IBMX), the extracellular CAMP concentration is a reliable parameter to assess the intracellular 
concentration of CAMP. 
Concerning our studies in the absence of IBMX, we have to consider how baclofen and 
dopamine inhibited a-MSH release. In view of the strong inhibition of o?-MSH release by these 
factors (this study) and the fact that the CAMP-analogue 8-bromo-CAMP is able to abolish 
baclofen-inhibited a-MSH release (3), we conclude that these factors inhibit a-MSH secretion by 
reducing the intracellular level of CAMP (see also 6). However, this raises the question why in 
this study the intracellular CAMP level does not seem to be affected by baclofen or dopamine 
treatment. Two explanations can be given. First, it may be that only a slight decrease in the 
intracellular CAMP level of the melanotrope cell, which might be of transient nature and be 
undetectable in our experimental approach, is sufficient to lead to the observed drastic (up to 60%) 
reduction in a-MSH release. Secondly, it may be that this strong reduction in secretion is the result 
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FIG. 4 
CAMP egress from superfused neurointermediate lobes of Xenopus laeuis 
without IBMX. Arrows represent the periods during which baclofen (BAC) 
or dopamine (DA) were present. 
of a similar drastic reduction of CAMP, not in the overall nemointermediate lobe, but only in a 
relatively small compartment within the lobe. This compartment might be a cellular 
subcompartment within each melanotrope cell, whereas the rest of the cellular CAMP might not 
be involved in the secretory process. These latter CAMP contents might largely determine the total 
concentration of CAMP within the lobe and obscure the secretion-related changes in the small 
compartment. The nature of such compartments is not known. Possibly particular cell organelles 
like components of the endoplasmatic reticulum are involved. The role of specific CAMP 
transporters in the plasma membrane also deserves particular attention 
As to the strongly stimulated CAMP release by baclofen and dopamine, this release could reflect 
a physiological mechanism to lower the intracellular CAMP concentration in the secretion- 
associated subcompartment of the melanotrope cell, thus leading to a reduced release of a-MSH. 
The slow increase of CAMP after the addition of the inhibitors BAC and DA (Fig. 3c,d,4) might 
reflect a slow build up of a sufficient CAMP level in the secretion subcompartment i  order to 
activate the transporter (16). 
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